Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions
MedComm · 2025-11 · 6 (11)
DOI: 10.1002/mco2.70451 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 02.11.2025. Verfasst von Jia Kuang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology The Affiliated Yongchuan Hospital of Chongqing Medical University Chongqing China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 229 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ischemic stroke remains a leading cause of global disability and death. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as potent lipid‐lowering agents with expanding therapeutic potential. Beyond robust low‐density lipoprotein cholesterol reduction, accumulating evidence suggests these drugs may confer benefits in ischemic stroke prevention and management. However, challenges regarding accessibility, real‐world efficacy, and integration into combination therapies persist, necessitating a comprehensive evidence synthesis. This review systematically consolidates the molecular mechanisms of PCSK9 inhibition and classifies current inhibitors. We delineate recent preclinical advances underscoring their neuroprotective and vasculoprotective effects, alongside critical findings from major clinical trials. These developments highlight promising avenues for both secondary prevention and acute‐phase treatment strategies. Collectively, this synthesis establishes a foundational framework for positioning PCSK9 inhibitors as transformative agents in stroke therapeutics and paves the way for precision neurovascular medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology The Affiliated Yongchuan Hospital of Chongqing Medical University Chongqing China.
- Department of Neurology The First Affiliated Hospital of Chongqing Medical University Chongqing China.
ORCID-Profile: Zhao Yang
Zitieren
APA
Kuang, J., Hao, L., Zhang, M., & Yang, Z. (2025). Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions. MedComm, 6(11). https://doi.org/10.1002/mco2.70451
Vancouver
Kuang J, Hao L, Zhang M, Yang Z. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions. MedComm. 2025;6(11). doi:10.1002/mco2.70451
BibTeX
@article{Kuang2025,
author = {Kuang, Jia and Hao, Lei and Zhang, Meibiao and Yang, Zhao},
title = {Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions},
journal = {MedComm},
year = {2025},
volume = {6},
number = {11},
doi = {10.1002/mco2.70451}
}
EUVIMED